A clinical screening program for topical chemotherapeutic drugs in psoriasis
- 1 July 1981
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Dermatology
- Vol. 117 (7) , 388-393
- https://doi.org/10.1001/archderm.117.7.388
Abstract
• In this national, multicenter cooperative study, a standardized drug screening program was designed and evaluated to test the clinical effectiveness of 30 topically applied chemotherapeutic drugs to psoriasis. Appropriate concentrations and vehicles for topical administration were selected with regard to potential systemic toxic effects and local skin irritation. The clinical testing consisted of a double-blind application of test agents to psoriatic plaques under occlusion daily for up to nine days. Drugs known to be topically active in psoriasis, eg, thiotepa, fluorouracil, and betamethasone valerate, were easily detected in the clinical protocol, confirming the validity of this topical drug screening program. Seven drugs produced substantial clinical improvement with evidence of clearing; nine drugs produced slight improvement; 14 drugs had no effect. No systemic toxic reactions occurred. This screen should be useful to test other potential antipsoriatic drugs and to evaluate potential animal model screens for their predictive values with these same drugs. (Arch Dermatol1981;117:388-393)This publication has 7 references indexed in Scilit:
- Glucocorticoid Inhibits Elevated Polyamine Biosynthesis in PsoriasisJournal of Investigative Dermatology, 1978
- Cell Proliferation Kinetics of Epidermis in the Essential Fatty Acid Deficient RatJournal of Investigative Dermatology, 1978
- Mycophenolic acid for psoriasisArchives of Dermatology, 1977
- Essential fatty acid deficient hairless mouse: a model of chronic epidermal hyperproliferationBritish Journal of Dermatology, 1977
- Topical Cycloheximide in PsoriasisJournal of Cutaneous Pathology, 1976
- Effect of Antimetabolites on Epidermal StructuresArchives of Dermatology, 1963
- Morphologic and Physiologic Effects of Chemotherapeutic Agents in Psoriasis11From the Dermatology Service, General Medicine Branch, National Cancer Institute, (National Institutes of Health, Public Health Service, U.S. Department of Health, Education, and Welfare) Bethesda, Maryland.Journal of Investigative Dermatology, 1959